TOMI Environmental Solutions, Inc.® (“TOMI”, “the Company”)
(NASDAQ: TOMZ), a global company specializing in disinfection and
decontamination, utilizing its premier Binary Ionization Technology
(BIT) platform through its SteraMist products - a hydrogen
peroxide-based mist and fog composed of ionized Hydrogen Peroxide
(iHP) announces that SteraMist has recently been featured in a
study investigating PPE sterilization in a sealed environment
chamber using biological indicator assemblies.
The COVID-19 pandemic has led to widespread shortages in
personal protective equipment (PPE) for clinicians and first
responders. Shortages in filtering facepiece respirators (FFR’s)
such as the N95 mask which are certified to filter 95% of airborne
particles are particularly problematic because these normally
single use items are a main stream of infection control.
In a recent study conducted by the Greater Boston
Pandemic Fabrication Team (PanFab), Harvard-MIT Center for
Regulatory Science, Harvard Medical School at the Dana Farber
Cancer Institute (DFCI) lab in conjunction with MIT and ICS labs, a
commercial laboratory accredited to perform testing by the National
Institute for Occupational Safety and Health (NIOSH), SteraMist
ionized Hydrogen Peroxide (iHP™) was applied directly to masks and
filtering facepiece respirators to gauge retention of filtration
ability after application. Five N95 masks from three separate
manufacturers were included in the study, and their ability to form
an airtight seal and filter aerosolized particles were observed
after SteraMist application. Results indicated that N95 masks
sterilized with SteraMist technology retained filtration up to ten
cycles – the largest number tested to date. The study concluded
that these results make for an “effective approach for a busy
medical center”.
The study states that four distinct hydrogen peroxide-based
technologies have been commercialized, with three having been given
Emergency Use Authorization (EUA) from the FDA despite limited
peer-reviewed data: Steris (Vaporized Hydrogen Peroxide, 30-35%
liquid H2O2), Advanced Sterilization Products’ Sterrad (Hydrogen
Peroxide Gas Plasma, 58-60% H2O2), and Bioquell (Hydrogen Peroxide
Vapor, 30-35% liquid H2O2). SteraMist’s iHP has the most
recent and complete data portfolio to date including meeting recent
National Institute for Occupational Safety and Health
standards.
The study also stated, “. . . our results support the use of iHP
as a PPE sterilant when delivered using a SteraMist-equipped
environment chamber. At this rate, assuming idealized staffing
and logistics, roughly 4800–7200 masks could be sterilized for use
per day given a typical 100-minute sterilization cycle. These
numbers could be increased with the addition of an overnight
workforce” (Cramer, Plana, Yang, et al.)
Dr. Halden Shane, TOMI CEO, commented: “As communities continue
to face the pandemic, TOMI is committed to spending the time and
resources required to provide transparency around the efficacy of
our solution by bringing SteraMist to healthcare and research
settings around the globe. This innovative use of SteraMist to
disinfect masks will help ease the ongoing burden on facilities to
keep a readily-available stock of PPE to help protect first
responders, hospital and medical staff, patients, and visitors.
Notably, this study demonstrated that the use of SteraMist in PPE
sterilization proved to be twice as effective as using other
similarly formulated alternatives. Since May of 2020, the FDA has
been evaluating our technology, and we are hopeful that the
positive results of this study will encourage this federal agency
to issue the Emergency Use Authorization (EUA) that will allow our
safe and effective technology to be widely distributed. SteraMist
technology has been tested and proven effective against the most
difficult to kill bacterial spores, including the successful kill
of SARS CoV-2 virus, as recently reported from the University of
Virginia. We’re pleased to have been included in this N95 and PPE
study and look forward to continuing to do our part to help keep
healthcare workers safe during the current pandemic and
beyond.”
The article can be read in full
at: https://www.nature.com/articles/s41598-021-81365-7 (Published
online January 21, 2021)
TOMI™ Environmental Solutions, Inc.: Innovating for a
safer world®
TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a
global decontamination and infection prevention company, providing
environmental solutions for indoor surface disinfection through the
manufacturing, sales and licensing of its premier Binary Ionization
Technology® (BIT™) platform. Invented under a defense grant in
association with the Defense Advanced Research Projects Agency
(DARPA) of the U.S. Department of Defense, BIT™ solution
utilizes a low percentage Hydrogen Peroxide as its only active
ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™).
Represented by the SteraMist® brand of products, iHP™ produces a
germ-killing aerosol that works like a visual non-caustic gas.
TOMI products are designed to service a broad spectrum of
commercial structures, including, but not limited to, hospitals and
medical facilities, cruise ships, office buildings, hotel and motel
rooms, schools, restaurants, meat and produce processing
facilities, military barracks, police and fire departments, and
athletic facilities. TOMI products and services have also
been used in single-family homes and multi-unit residences.
TOMI develops training programs and application protocols
for its clients and is a member in good standing with The American
Biological Safety Association, The American Association of Tissue
Banks, Association for Professionals in Infection Control and
Epidemiology, Society for Healthcare Epidemiology of America,
America Seed Trade Association, and The Restoration Industry
Association.
For additional information, please
visit http://www.tomimist.com/ or contact us
at info@tomimist.com.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute
“forward-looking statements” as defined in the Private Securities
Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking
statements are identified by such words and phrases as “we expect,”
“expected to,” “estimates,” “estimated,” “current outlook,” “we
look forward to,” “would equate to,” “projects,” “projections,”
“projected to be,” “anticipates,” “anticipated,” “we believe,”
“could be,” and other similar phrases. All statements addressing
operating performance, events, or developments that we expect or
anticipate will occur in the future, including statements relating
to revenue growth, earnings, earnings-per-share growth, or similar
projections, are forward-looking statements within the meaning of
the Reform Act. They are forward-looking, and they should be
evaluated in light of important risk factors that could cause our
actual results to differ materially from our anticipated results.
The information provided in this document is based upon the facts
and circumstances known at this time. We undertake no obligation to
update these forward-looking statements after the date of this
release.
INVESTOR RELATIONS CONTACTJohn Nesbett/Jennifer BelodeauIMS
Investor Relationsjnesbett@imsinvestorrelations.com
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From Apr 2024 to May 2024
TOMI Environmental Solut... (NASDAQ:TOMZ)
Historical Stock Chart
From May 2023 to May 2024